BIOSERENITY, INC.

WeHealth™ Digital Medicine and BioSerenity Initiate a New Phase to Accelerate Cardioskin™ Commercialization

Retrieved on: 
Tuesday, February 23, 2021
Health informatics, Health, Digital health, Digital medicine, Medicine, Health professional, Laboratoires Servier

PARIS and ATLANTA, Feb. 23, 2021 /PRNewswire/ --WeHealth Digital Medicine, Servier Group's e-health division, and BioSerenity, today announced that BioSerenity acquired the global distribution rights to CardioskinTM, the first WeHealthTMdigital solution co-developed with a start-up, to accelerate the commercialization of Cardioskin.

Key Points: 
  • PARIS and ATLANTA, Feb. 23, 2021 /PRNewswire/ --WeHealth Digital Medicine, Servier Group's e-health division, and BioSerenity, today announced that BioSerenity acquired the global distribution rights to CardioskinTM, the first WeHealthTMdigital solution co-developed with a start-up, to accelerate the commercialization of Cardioskin.
  • "In today's world, digital health care is becoming more prevalent," said Pierre-Yves Frouin, Chief Executive Officer of BioSerenity.
  • "Dr. David Guez, founder of Servier's WeHealth Digital Medicine, had the vision to develop remote Cardiology.
  • WeHealth Digital Medicine, aims to improve the daily life of patients and health professionals' alike using digital means.

WeHealth™ Digital Medicine and BioSerenity Initiate a New Phase to Accelerate Cardioskin™ Commercialization

Retrieved on: 
Tuesday, February 16, 2021
Medicine, Laboratoires Servier, Digital medicine

PARIS and ATLANTA, Feb. 16, 2021 /PRNewswire/ --WeHealth Digital Medicine (e-health division of the Servier Group) and BioSerenity announced today that BioSerenity gains global distribution rights for Cardioskin, the first WeHealth digital Solution co-developped with a start-up, to accelerate the commercialization of Cardioskin.

Key Points: 
  • PARIS and ATLANTA, Feb. 16, 2021 /PRNewswire/ --WeHealth Digital Medicine (e-health division of the Servier Group) and BioSerenity announced today that BioSerenity gains global distribution rights for Cardioskin, the first WeHealth digital Solution co-developped with a start-up, to accelerate the commercialization of Cardioskin.
  • BioSerenity acquires Cardioskin global distribution rights and associated trademarks, in return for which WeHealth Digital Medicine will receive from BioSerenity immediate payments and variable fees depending on future net sales.
  • Dr. David Guez, founder of WeHealth Digital Medicine, had the vision to develop remote Cardiology.
  • In an open innovative approach, WeHealth Digital Medicine identifies the most promising start-ups in e-health, in France and internationally, to co-develop solutions.

BioSerenity Announces FDA Clearance for Electroencephalography (EEG) Wearable Device System

Retrieved on: 
Tuesday, January 5, 2021
Neurology, Health care, Medicine

Together, the IceCap and Neuronaute system are a unique and ideal combination to facilitate access to care in a variety of settings including rural and remote environments.

Key Points: 
  • Together, the IceCap and Neuronaute system are a unique and ideal combination to facilitate access to care in a variety of settings including rural and remote environments.
  • The Neuronaute system assists healthcare professionals in the diagnosis, monitoring and assessment of epilepsy and other neurological disorders in adult patients.
  • The IceCap (Immediate Care Encephalography) Cap is a wearable medical device used together with the Neuronaute system.
  • "With FDA clearance to market the Neuronaute system and IceCap, we can deliver high-quality, cost-effective diagnostic care by remotely connecting patients in need with neurological specialists anytime and anywhere."

BioSerenity, Leader in Healthcare as a Service (HaaS), Develops Virtual Clinics Providing Greater Access to Care for People with Epilepsy

Retrieved on: 
Monday, July 13, 2020
Articles, Health, Health informatics, Assistive technology, Telehealth, Telemedicine, Electroencephalography, Clinic, Health care, eHealth

The COVID-19 pandemic places an even greater burden on routine healthcare services in addition to changing the way medical professionals engage with their patients.

Key Points: 
  • The COVID-19 pandemic places an even greater burden on routine healthcare services in addition to changing the way medical professionals engage with their patients.
  • Virtual care solutions better connect people living with epilepsy to obtain electroencephalogram (EEG) diagnostic services and provide continuity of care over great distances.
  • Virtual epilepsy clinics allow remote specialist health management in areas where there are an insufficient number (or no) specialists available.
  • We are excited to share an overview and introduction of how virtual epilepsy clinic telehealth services can provide patients greater access to care.

BioSerenity, Leader in Healthcare as a Service (HaaS), Helps Advance Understanding of COVID-19 Neurological Impact

Retrieved on: 
Thursday, June 18, 2020
Branches of biology, Medicine, Clinical medicine, Brain–computer interfacing, Electroencephalography, Electrophysiology, Neurophysiology, Neurotechnology, Sedation

Via these collaborations, we were one of the first to discover EEG anomalies likely associated with Covid-19.

Key Points: 
  • Via these collaborations, we were one of the first to discover EEG anomalies likely associated with Covid-19.
  • Patients presented with altered mental status, had delayed awakening, or poor arousal after being taken off sedation.
  • BioSerenity will provide data to help physicans diagnose over 30,000 patients suffering from neurological disorders this year.
  • Headquartered in Paris, France, and Atlanta, GA, USA, BioSerenity is an innovative medical technology company focused on Healthcare as a Service, IoMT, A.I.